SEARCH

SEARCH BY CITATION

References

  • Anderson, D.E., Bieganowska, K.D., Bar-Or, A., Oliveira, E.M.L., Carreno, B., Collins, M., Hafler, D.A. (2000) Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nature Medicine, 6, 211214.DOI: 10.1038/72323
  • Antica, M., Kusic, B., Spaventi, R., Jaksic, B., Vitale, B. (1993) Functional differences of T cells in B-chronic lymphocytic leukaemia. Leukemia and Lymphoma, 9, 133140.
  • Ayanlar-Batuman, O., Ebert, E., Hauptman, S. (1986) Defective interleukin-2 production and responsiveness to T ce.lls in patients with chronic lymphocytic leukaemia of B cell variety. Blood, 67, 279284.
  • Benjamini, E., Sunshine, G., Leskowitz, S. (1996) Immunology, a Short Course, 3rd edn, pp. 199202, Wiley-Liss, New York.
  • Bonnefoy-Berard, N. & Revillard, J.P. (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. Journal of Heart and Lung Transplantation, 15, 435442.
  • Brusa, P., Casullo, R., Dosio, F., Cattel, L., Beltramini, S., Chiapetta, R., Tosetti, L., Andorno, E., Salizzoni, M. (1998) OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients. European Journal of Drug Metabolism and Pharmokinetics, 23, 301306.
  • Cantwell, M., Hua, T., Pappas, J., Kipps, T. (1997) Acquired CD40-ligand deficiency in chronic lymphocytic leukaemia. Nature Medicine, 3, 984989.
  • Chiorazzi, N., Fu, S.F., Montazeri, G., Kunkel, H.G., Rai, K., Gee, T. (1979) T cell helper defect in patients with chronic lymphocytic leukaemia. Journal of Immunology, 122, 10871090.
  • Clark, L.B., Foy, T., Noelle, R.J. (1996) CD40 and its ligand. Advances in Immunology, 63, 4378.
  • Dianzani, U., Omede, P., Marmont, F., DiFranco, D., Fusaro, D., Bragardo, M. (1994) Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukaemia: correlation with disease status and neoplastic phenotype. Blood, 83, 21982205.
  • Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D., Noelle, R.J. (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunology Today, 15, 406410.
  • Figdo, C.G., Van Kooyk, Y., Keizer, G.D. (1990) On the mode of action of LFA-1. Immunology Today, 11, 277280.
  • Foa, R., Giovarelli, M., Jemma, C., Fierro, M.T., Lusso, P., Ferrando, M.L., Lauria, F., Forni, G. (1985) Interleukin-2 (IL 2) and interferon-γ production by T lymphocytes from patients with B-chronic lymphocytic leukaemia: evidence that normally released IL-2 is absorbed by the neoplastic B cell population. Blood, 66, 614618.
  • Grewal, I.S. & Flavell, R.A. (1996) A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunology Today, 17, 410414.DOI: 10.1016/0167-5699(96)10030-x
  • Grewal, I.S. & Flavell, R.A. (1997) The CD40 Ligand: at the center of the immune universe? Immunologic Research, 16, 5970.
  • Han, T., Ozer, H., Henderson, E.S., Dadey, B., Nussbaum-Blumenson, A., Barcos, M. (1981) Defective immunoregulatory in T-cell function in chronic lymphocytic leukaemia. Blood, 58, 11821189.
  • Hill, S.J., Peters, S.H., Ayliffe, M.J., Merceica, J., Bansal, A.S. (1999) Reduced IL-4 and interferon-γ (IFN-γ) expression by CD4 T cells in patients with chronic lymphocytic leukaemia. Clinical Experimental Immunology, 117, 811.
  • Kay, N. (1981) Abnormal T-cell subpopulation function in CLL: excessive suppressor (Tγ) and deficient helper (Tμ) activity with respect to B-cell proliferation. Blood, 57, 418420.
  • Kay, N., Johnson, J.D., Stanek, R., Douglas, S.D. (1979) T-cell subpopulations in chronic lymphocytic leukaemia: abnormalities in distribution and in vitro receptor maturation. Blood, 54, 540543.
  • Krummel, M.F. & Allison, J.P. (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. Journal of Experimental Medicine, 182, 459465.
  • Lenschow, D.J., Walunas, T.L., Bluestone, J.A. (1996) CD28/B7 system of T cell costimulation. Annual Review of Immunology, 14, 233258.
  • Lub, M., Van Kooyk, Y., Figdo, C.G. (1995) Ins and outs of LFA-1. Immunology Today, 16, 479484.
  • Makgoba, M.W., Sanders, M.E., Shaw, S. (1989) The CD2-LFA-3 and LFA-1-ICAM-1 pathways: relevance to T-cell recognition. Immunology Today, 10, 417422.
  • Mu, X., Kay, N., Gosland, M., Jennings, C. (1997) Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. British Journal of Haematology, 96, 733735.
  • Peller, S. & Kaufman, S. (1991) Decreased CD45RA T cells in B-cell chronic lymphatic leukaemia patients: correlation with disease stage. Blood, 78, 15691573.
  • Prieto, A., Garcia-Suarez, J., Reyes, E., Lapena, P., Hernandez, M., Alvarez-Mon, M. (1993) Diminished DNA synthesis in T cells from B chronic lymphocytic leukaemia after phytohaemagglutinin, anti-CD3 and phorbol myristate acetate mitogenic signals. Experimental Hematology, 21, 15631569.
  • Reinke, P., Schwinzer, H., Hoflich, C., Ode-Hakin, C., Docke, W.D., Frei, U., Volk, H.D. (1997) Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection. Immunology Letters, 57, 151153.DOI: 10.1016/s0165-2478(97)00092-8
  • Rossi, E., Matutes, E., Morilla, R., Owusu-Ankomah, K., Heffernan, A., Catovsky, D. (1996) Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukaemia. Leukaemia, 10, 494497.
  • Schweitzer, A.N. & Sharpe, A.H. (1998) The complexity of the B7–CD28/CTLA-4 co- stimulatory pathway. Agents and Actions Supplements, 49, 3343.
  • Sgro, C. (1995) Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology, 105, 2329.DOI: 10.1016/0300-483x(95)03123-w
  • Taniguchi, T. & Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell, 73, 58.
  • Tinhofer, I., Marschitz, I., Kos, M., Henn, T., Egle, A., Villunger, A., Greil, R. (1998) Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand tumour cells in B chronic lymphocytic leukaemia. Blood, 91, 42734281.
  • Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., Sharpe, A.H. (1989) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multi-organ tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3, 541547.
  • Totterman, T.H., Carlsson, M., Simonsson, B., Bengtsson, M., Nilsson, K. (1989) T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood, 2, 786792.
  • Waldmann, T. (1986) The structure, function and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science, 232, 727732.
  • Waldmann, T. (1991) The Interleukin-2 receptor. Journal of Biological Chemistry, 266, 26812684.
  • Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., Bluestone, J.A. (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity, 1, 405413.